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Abstract 23 
Background: Cancer patients hospitalized for an acute medical illness are considered to be at high 24 
risk of venous thromboembolism (VTE). Information on bleeding and symptomatic VTE in these 25 
patients remains scant. The objectives of this study were to evaluate the incidence of bleeding and 26 
VTE during hospitalization and after discharge in a prospective cohort of hospitalized medically-ill 27 
cancer patients. 28 
Methods: Consecutive patients with active cancer admitted for an acute medical illness. The 29 
primary outcome was the incidence of clinically relevant bleeding. Secondary outcomes included 30 
symptomatic and incidentally detected VTE. Outcomes were recorded during hospitalization up to 31 
three months after discharge. 32 
Results: The study population consisted of 330 patients with a mean age of 73.2 (±12.1) years. 33 
During a median hospitalization of eight days, six patients (1.8%) developed a clinically relevant 34 
bleeding. Pharmacological thromboprophylaxis was administered to four of these six patients 35 
(66.6%), and 108 of 324 (33.3%) patients without bleeding. Twelve (3.6%) were diagnosed with 36 
VTE, of whom two had received thromboprophylaxis. In ten patients, VTE was detected 37 
incidentally. After discharge, 11 patients experienced major bleeding and two developed 38 
symptomatic VTE during a median follow-up of 92 days (range 19 - 110). Two thirds of all major 39 
bleeding events were gastrointestinal, and 87% occurred in patients with gastrointestinal or 40 
genitourinary cancer. 41 
Conclusions: In patients with active cancer admitted for an acute medical illness, the risk of 42 
bleeding and symptomatic VTE appeared to be low during hospitalization. After discharge, the risk 43 
of bleeding was higher and significantly outweighed that of VTE. 44 
45 
Keywords: Hemorrhage, venous thromboembolism, neoplasm, hospitalization, prospective studies 46 
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Highlights 47 
• In patients with active cancer admitted for an acute medical illness, the incidence of
clinically relevant bleeding and symptomatic venous thromboembolism was low during
hospitalization
• After discharge, the rate of bleeding was higher and significantly outweighed that of
venous thromboembolism
• Prophylaxis for venous thromboembolism in these patients is underused relative to
guideline recommendations
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Abbreviations 67 
CI = Confidence Intervals 68 
OR = Odds Ratio 69 
RCT = Randomized Clinical Trials 70 
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Introduction 82 
Patients with cancer who are hospitalized for an acute medical illness are considered to be at 83 
increased risk of venous thromboembolism (VTE) [1-4]. Prospective data on the incidence of 84 
bleeding complications and symptomatic VTE in this high-risk population are lacking and 85 
recommendations on the use of pharmacological thromboprophylaxis in these patients are largely 86 
based on indirect evidence [1-8]. In addition, a pooled analysis of 307 hospitalized medically-ill 87 
cancer patients from three placebo-controlled randomized clinical trials (RCTs) found that 88 
thromboprophylaxis was not associated with a significant reduction of the incidence of VTE [9]. It 89 
is of note that nearly one third of hospitalized patients with cancer may have relative 90 
contraindications to pharmacological prophylaxis, and among those without apparent 91 
contraindications, still one third does not receive any prophylaxis [10]. The low frequency of use of 92 
recommended VTE prophylaxis in these patients could be due to many factors, including 93 
physicians’ awareness as well as lack of solid efficacy data and direct evidence on safety. In 94 
addition, the risk of VTE in some hospitalized cancer patients may be perceived as insufficiently 95 
high to justify the risks and burden of daily parenteral prophylaxis. 96 
Cancer patients may remain at risk of VTE after hospital discharge and could take advantage 97 
of extended pharmacological prophylaxis [11-12]. However, the increased bleeding tendency and 98 
risk of major bleeding complications in these patients could offset the benefits of 99 
thromboprophylaxis [11-12]. It is therefore of outmost importance to clarify the trade-off between 100 
bleeding and VTE both during hospitalization and after discharge to inform the decision on the use 101 
of thromboprophylaxis. 102 
The aim of this study was to evaluate the incidence of clinically relevant bleeding and VTE 103 
in a prospective cohort of cancer patients admitted for an acute medical illness. 104 
105 
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Materials and Methods 106 
Study population 107 
We conducted a prospective, observational, non-interventional cohort study including a consecutive 108 
series of patients with active cancer hospitalized for an acute medical illness in our Internal 109 
Medicine Unit in Chieti, Italy from April 2015 to August 2017. Active cancer was defined by any 110 
of the following: a) cancer diagnosis within the past six months, b) recurrent, regionally advanced, 111 
or metastatic disease, c) ongoing cancer treatment or any treatment for cancer during six months 112 
prior to hospitalization, or d) hematologic malignancy not in complete remission. Patients were 113 
excluded if they were on anticoagulant treatment for other indications or refused to sign informed 114 
consent forms. In addition, we excluded patients if active bleeding or VTE were the cause of 115 
hospitalization or developed within 24 hours of admission. The study was approved by the local 116 
institutional review board and all patients provided informed consent. The study is registered in 117 
clinicaltrials.gov with accession number NCT02407717. 118 
119 
Study outcomes 120 
The primary outcome of the study was the incidence of clinically relevant bleeding during 121 
hospitalization, which was defined as the composite of major and clinically relevant non-major 122 
bleeding. Major bleeding was defined according to the definition of the International Society on 123 
Thrombosis and Haemostasis as overt bleeding that was fatal, occurred in a critical area or organ 124 
(e.g. intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or 125 
intramuscular with compartment syndrome), resulted in a drop in hemoglobin level of 2 g/dL or 126 
more (i.e. 1.24 mmol/L), or lead to the transfusion of two or more units of whole blood or packed 127 
red blood cells [13]. A clinically relevant non-major bleeding was defined as bleeding that did not 128 
fit the criteria for major bleeding, but required a medical intervention by a healthcare professional 129 
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and/or required an increased level of care. Following discharge, a bleeding event was also 130 
considered as clinically relevant non-major when it led to hospitalization and/or prompted a face-to-131 
face evaluation. 132 
Secondary outcomes included symptomatic and incidental VTE during hospitalization; 133 
bleeding events (major and clinically relevant non-major bleeding), symptomatic and incidental 134 
VTE, and all-cause mortality up to three months after discharge. VTE, which included deep vein 135 
thrombosis of the lower extremities and pulmonary embolism, had to be objectively confirmed by 136 
standard diagnostic methods which included compression ultrasonography for deep vein thrombosis 137 
and computed tomography pulmonary angiography or lung scan for pulmonary embolism [14]. 138 
Deep venous thrombosis at other sites (e.g. splanchnic vein thrombosis) was also recorded. 139 
Incidental VTE was defined as VTE detected during imaging tests performed for other reasons than 140 
VTE suspicion, such as the diagnostic work-up of the medical illness causing hospitalization or its 141 
complications.  142 
143 
Study procedures 144 
We collected information on demographics (age, gender, body mass index), cancer characteristics 145 
(metastatic disease, recent cancer treatment), co-morbidities (e.g. renal insufficiency, 146 
thrombocytopenia, cardiovascular disease), VTE risk factors (e.g. history of VTE), reasons for 147 
hospitalization, and concomitant treatment (e.g. antiplatelet agents). The decision on the use and 148 
duration of thromboprophylaxis was not dictated by study protocol and was left to the treating 149 
physician who was asked to report the reasons for withholding thromboprophylaxis at admission. A 150 
phone or visit contact was planned at three months after discharge in all patients to verify the 151 
development of thrombotic or bleeding events. 152 
153 
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Statistical considerations 154 
Continuous variables were reported as mean (± standard deviations) or median (range) depending 155 
on distribution, categorical variables as number (percentages). The incidence with 95% Wilson 156 
confidence intervals (CIs) of bleeding and VTE events were calculated during hospitalization and 157 
up to three months after discharge. The association between use of pharmacological 158 
thromboprophylaxis and patient characteristics was evaluated reporting odds ratio (OR) and the 159 
relative 95% CIs [12]. Exploratory analyses were conducted to evaluate the discriminative 160 
performance of the score derived in the International Medical Prevention Registry on Venous 161 
Thromboembolism (IMPROVE) study for bleeding events, and of the Khorana and Padua 162 
prediction models for VTE [12, 15-16]. Patients with seven points or higher on the IMPROVE 163 
score were considered at high risk, those with six points or less at low risk [11-12]. The Khorana 164 
score was assessed at the conventional threshold of three points as well as at the exploratory two 165 
and four cut points. In the absence of adequate information from previous studies on the incidence 166 
of the primary outcome in patients with active cancer hospitalized for a medical illness [9], a formal 167 
sample size calculation was not performed. We aimed to enroll a cohort of at least 300 consecutive 168 
patients. 169 
170 
Results 171 
A total of 535 patients were evaluated for inclusion and 205 excluded, mainly because of an 172 
ongoing use of anticoagulant therapy (n = 96) or active bleeding on admission (n = 52; Figure). The 173 
final population consisted of 330 hospitalized patients with a mean age of 73.2 (SD 12.1) years. The 174 
most frequent cancer types were gastrointestinal (n = 73, 22.1%), lung (n = 52, 15.8%), and prostate 175 
(n = 40, 12.1%). Baseline characteristics of the study population and reasons for hospitalization are 176 
reported in Table 1. 177 
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One hundred and thirty-nine patients out of 330 (42%) did not receive pharmacological 178 
thromboprophylaxis due to the presence of concomitant bleeding risk factors. Treating physicians 179 
reported the following reasons for withholding thromboprophylaxis: history of major bleeding (n = 180 
5, 1.5%), active gastroduodenal ulcer (n = 2, 0.6%), thrombocytopenia (n = 4, 1.2%), moderate to 181 
severe renal insufficiency (n = 27, 8.2%), moderate to severe anemia (n = 93, 28.2%), liver 182 
dysfunction (n = 7, 2.1%), and patient refusal (n = 1, 0.3%). 183 
Among 191 patients without reported contraindications for anticoagulation, 112 (58.6%) 184 
received pharmacological prophylaxis during hospitalization, while in the remaining 79 patients the 185 
risk of VTE was not perceived high enough to use thromboprophylaxis. Prophylaxis was 186 
administered for a median of seven days (range 1 to 35) and consisted of low-molecular-weight 187 
heparin (n = 91) or fondaparinux (n = 21). Patients more likely to receive pharmacological 188 
thromboprophylaxis were 75 years or older (OR 2.6;95%CI, 1.46 to 4.61), had metastatic disease 189 
(OR 1.79;95% CI, 1.13 to 2.85), or worse ECOG performance status (OR 1.70;95%CI, 1.26 to 190 
2.30). After discharge, thromboprophylaxis with heparin or fondaparinux was administered to 48 191 
out of 289 alive patients (17%) for a median of 15 days (range 2 to 90). No patient received oral 192 
anticoagulants or mechanical prophylaxis with elastic compression stockings or intermittent 193 
pneumatic compression devices during any phase of the study. 194 
195 
Clinically relevant bleeding 196 
During a median hospitalization of eight days (range 1 to 96), six patients (1.82%; 95% CI 0.84 to 197 
3.91) had clinically relevant bleeding, which included four major bleeding (1.21%; 95% CI 0.47 to 198 
3.07)  of the gastrointestinal (n = 2) or genitourinary (n = 2) tracts, and two clinically relevant non-199 
major bleeding (0.61%; 95% CI 0.17 to 2.18; Tables 2 and 3). Pharmacological thromboprophylaxis 200 
was administered to four of these six patients (66.6%) and 108 of 324 (33.3%) patients without 201 
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bleeding. The risk of clinically relevant bleeding was fivefold higher in patients classified as at high 202 
risk by the IMPROVE score (n = 56) compared to those at low risk (n = 274, 5.3% versus 0.8%, OR 203 
5.1;95%CI, 1.0 to 26.0, p = 0.049). 204 
After discharge, there were eleven major bleeding and one clinically relevant non-major 205 
bleeding (4.15%; 95% CI 2.16 to 7.14) out of 289 patients during a median follow-up of 92 days 206 
(range 19 to 110). Only one of these twelve patients was on pharmacological thromboprophylaxis. 207 
One patient had an intracranial hemorrhage and nine patients had a major bleeding, mostly 208 
gastrointestinal, which required the transfusion of two or more units of packed red blood cells 209 
(Table 3). A 79 years old man with metastatic cancer of the bladder developed a fatal 210 
retroperitoneal bleeding from the rupture of an aneurysm of the abdominal aorta. One patient was 211 
admitted to the Emergency for rectal bleeding, which did not require blood transfusion and was 212 
classified as clinically relevant non-major bleeding.  213 
214 
Venous thromboembolism 215 
Overall, 12 out of 330 patients (3.64%; 95% CI 1.89% to 6.27%) were diagnosed with VTE during 216 
hospitalization (Tables 2 and 4). Ten VTEs (83%) including seven pulmonary embolism and three 217 
deep vein thrombosis were detected incidentally by computed tomography scanning performed as 218 
part of the diagnostic work-up of the disease leading to hospitalization (Table 4). The most 219 
proximal pulmonary artery was segmental in six patients, whereas the main or lobar artery were 220 
involved in one patient each. Pulmonary embolism was bilateral in one case. An 82-year old man 221 
with prostate cancer complained of pain and edema of the lower limb on the fourth day of 222 
hospitalization. Compression ultrasonography confirmed deep vein thrombosis of the popliteal and 223 
posterior tibial veins. Another 80-year old man with metastatic lung cancer who was hospitalized 224 
due to heart failure with pulmonary congestion, complained of worsening dyspnea on day twelve. 225 
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Computed tomography pulmonary angiography detected multiple segmental and subsegmental 226 
pulmonary embolism. A patient with liver cancer was diagnosed with incidental splanchnic vein 227 
thrombosis. 228 
During hospitalization, two out of 112 patients (1.79%; 95% CI 0.22% to 6.30%) on 229 
pharmacological thromboprophylaxis developed VTE versus ten out of 218 (4.59%; 95% CI 2.22% 230 
to 8.27%) without thromboprophylaxis. Five out of 49 patients (10.2%) with a Khorana score ≥3 231 
developed VTE compared to 7 of 281 patients (2.5%) with a score below 2 points (OR 4.4;95%CI, 232 
1.3 to 14.6). A Khorana score ≥4 was associated with a sevenfold higher risk of in-hospital VTE 233 
(20% versus 3.1%, respectively, OR 7.7;95%CI, 1.4 to 41.3), whereas the threshold of 2 cut-points 234 
and the Padua prediction model did not discriminate between patients at high versus low risk of 235 
VTE (OR for the Khorana ≥2, 1.5; 95%CI, 0.5 to 4.8, and OR for the Padua model, 0.68;95%CI, 236 
0.18 to 2.6). 237 
After discharge, two symptomatic VTEs occurred in 289 patients (0.69%; 95% CI 0.08% to 238 
2.48%). A 56-year old woman with lung cancer was diagnosed with symptomatic pulmonary 239 
embolism ten weeks after discharge and a man with metastatic cancer of the testicle who had re-240 
started chemotherapy one week after hospitalization developed symptomatic bilateral femoral deep 241 
vein thrombosis 34 days after discharge. Both these patients had received prophylactic low-242 
molecular-weight heparin during their hospital stay until the post-discharge VTE . 243 
244 
Other events 245 
Forty-one patients died in-hospital (12.42%; 95% CI 9.07% to 16.48%) and 134 during follow-up 246 
(46.37%; 95% CI 40.51% to 52.30%). An autopsy was not performed in these patients and the 247 
ultimate cause of death was not ascertained. In those who died at home, the most likely cause of 248 
death according to the treating physician was the progression of cancer or worsening of the medical 249 
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illness. Fifty-six patients were re-hospitalized during follow-up and two died during re-250 
hospitalization due to cancer progression and septic shock with multiorgan failure, respectively. 251 
There were no cardiovascular or cerebrovascular complications during hospitalization or follow-up. 252 
253 
Discussion 254 
The incidence of clinically relevant bleeding and symptomatic VTE was low during hospitalization. 255 
After discharge, the background risk of bleeding in absence of thromboprophylaxis was higher and 256 
significantly outweighed the one of VTE. The current study showed underuse of recommended 257 
VTE prophylaxis in cancer patients hospitalized for an acute medical illness. 258 
The overall incidence of clinically relevant bleeding during hospitalization was 1.8%, 259 
consistent with prior studies [17,18]. A lower rate was reported in a post-hoc analysis of the 260 
CERToparIn For thromboprophYlaxis in medical patients (CERTIFY) study, which could hinge on 261 
differences in outcome definitions, length of observation, or study populations as suggested by the 262 
fourfold higher in-hospital mortality in our cohort compared to that study [19]. 263 
The incidence of VTE during hospitalization was 3.6%, consistent with the rate of 3.8% 264 
observed in a recent retrospective cohort of 2780 cancer inpatients [20]. In agreement with prior 265 
studies, the large majority of these VTEs were detected incidentally [17,19,21]. Although incidental 266 
VTE is still an area of investigation and debate, available data suggest that incidental VTE, in 267 
particular incidental pulmonary embolism, has important implications for overall and cancer-268 
specific prognosis [22]. Treatment and prevention of incidental VTE are currently regarded as 269 
important as for symptomatic VTE [23]. The onset of incidental VTE in this patient population 270 
remains unclear and we cannot rule out that part of these events developed prior to hospitalization. 271 
Prospective data on the incidence of bleeding and VTE in cancer patients after 272 
hospitalization for an acute medical illness are lacking [24-25]. In a relatively sick population with a 273 
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high mortality rate, we observed a high incidence of clinically relevant bleeding, most off-274 
thromboprophylaxis, which significantly outweighed the incidence of VTE. Thus, the trade-off 275 
between bleeding and thrombotic events was different compared to the in-hospital phase when the 276 
risk of bleeding or symptomatic VTE was low. Of note, two thirds of all major bleeding events 277 
during study were gastrointestinal, and 87% occurred in patients with gastrointestinal or 278 
genitourinary cancer, suggesting a higher bleeding tendency in these tumor types. 279 
Bleeding and thrombotic risk stratification are strongly advocated by most clinical 280 
practice guidelines to guide the use of thromboprophylaxis in hospitalized patients, but validated 281 
risk assessment tools for patients with cancer are not yet available [1,4]. The Padua Prediction 282 
Score was empirically derived for estimating the overall risk of thrombosis in hospitalized 283 
medically-ill patients [16]. The usefulness of this model has been questioned, and preliminary 284 
observations suggested that the score had limited influence, if any, on the decision about the use of 285 
thromboprophylaxis in hospitalized cancer patients [10, 26-27]. In the current study population, the 286 
Padua score appeared not to discriminate patient risk of VTE, whereas the Khorana score, originally 287 
developed to predict VTE in cancer outpatients, seemed to hold discriminative value, in agreement 288 
with recent observations [20]. While the IMPROVE score seemed able to identify a subgroup at 289 
high bleeding risk, the relatively low number of patients with some of the characteristics included in 290 
this model represent a limitation. 291 
Strengths of the current study are the prospective design, the a-priori definition of active 292 
cancer status, and the follow-up for VTE and bleeding complications after discharge. The study did 293 
not include patients admitted for minor procedures or short chemotherapy infusion, thus our 294 
findings may not extend to these patients. As the focus was on patients with active cancer, the 295 
results may not apply to those with a history of cancer. The lack of randomization and statistical 296 
power precluded a formal evaluation of the efficacy and safety of VTE thromboprophylaxis. Of 297 
note, about 40% of the patients in our study were perceived as having a relative contraindication to 298 
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anticoagulation or a risk of VTE not sufficiently high to justify the use of pharmacological 299 
thromboprophylaxis. Similar findings were reported in a large cross-sectional study by Zwicker and 300 
colleagues where prophylaxis was withheld in nearly one third of patients [10].  301 
 In summary, patients with cancer admitted for an acute medical illness presented a low risk 302 
of symptomatic VTE despite the relative underuse of prophylaxis and had infrequent bleeding 303 
complications during hospitalization. After discharge, however, the background risk of bleeding in 304 
absence of thromboprophylaxis is high and outweighs that of VTE. Large randomized controlled 305 
trials specifically focusing on cancer patients or even specific tumor subgroups are warranted to 306 
clarify the safety and efficacy of VTE thromboprophylaxis in this challenging group of patients. 307 
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Table 1. Baseline characteristics of study participants 435 
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 Patients 
n = 330 
Age in years, mean (SD)    73.2 (12.1) 
Female sex 134 (40.6 %) 
Body mass index in kg/m2, mean (SD)   24.0 (3.4) 
Smoking 
 Current 
 Former 
 
  14 (4.2 %) 
  36 (10.9 %) 
Cancer type 
 Lung 
 Colorectal 
 Gastric 
 Breast 
 Liver 
 Pancreas 
 Gynecological 
 Prostate 
 Unknown primary 
 Leukemia/Lymphoma 
 Primary brain 
 Other 
 
  52 (15.8 %) 
  57 (17.3 %) 
  16 (4.8 %) 
  33 (10.0 %) 
  12 (3.6 %) 
  19 (5.8 %) 
  15 (4.5 %) 
  40 (12.1 %) 
    3 (0.9 %) 
  15 (4.5 %) 
    9 (2.7 %) 
  59 (17.9 %) 
Metastasis 172 (52.1 %) 
Medical Illness causing hospitalization 
 Acute heart failure 
 Acute respiratory insufficiency 
 Acute infection 
 Acute inflammatory or rheumatological disease 
 Nausea-vomiting 
 Malnutrition-dehydration 
 Dysphagia 
 Diarrhea 
 Obstructive jaundice 
 Intestinal (sub-)occlusion 
 Refractory pain 
 Cancer Progression/chemotherapy toxicity 
 Acute stroke/Transient ischemic attack 
 Arrhythmia  
 Cancer  cachexia  
 Pleural effusion 
 Worsening ascites 
 Syncope 
 Seizures 
 Other 
 
  22 (6.7 %)    
  28 (8.5 %) 
  38 (11.5 %) 
  16 (4.8 %) 
  32 (9.7 %) 
  21 (6.4 %) 
    9 (2.7 %) 
    8 (2.4 %) 
    8 (2.4 %) 
  13 (3.9 %) 
  29 (8.8 %) 
  42 (12.7 %) 
    9 (2.7 %) 
    3 (0.9 %) 
  27 (8.2 %) 
  19 (5.8 %) 
  19 (5.8 %) 
    4 (1.2 %) 
    2 (0.6 %) 
  11 (3.3 %) 
History of stroke or transient ischemic attack   18 (5.4 %) 
Chronic renal insufficiency   34 (10.3 %) 
Central venous catheter     2 (0.6 %) 
Previous venous thromboembolism     9 (2.7 %) 
Cancer treatment ≤ 3 months 
 Chemotherapy 
 Radiotherapy 
 Chemo-radiotherapy 
 Hormonal treatment 
 
  62 (18.8 %) 
  13 (3.9 %) 
  15 (4.5 %) 
  23 (7.0 %) 
Trauma or surgery ≤ 3 months   23 (7.0 %) 
  
Table 1. "Continued" 436 
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Antiplatelet agents   68 (20.6 %) 
Non Steroidal Anti-Inflammatory drugs   16 (4.8 %) 
Previous gastroduodenal ulcer     6 (1.8 %) 
ECOG 
0 
1 
2 
3 
4 
 
    5 (1.5 %) 
  42 (12.7 %) 
120 (36.4 %) 
147 (44.5 %) 
  16 (4.8 %) 
Padua score, median (range)     5 (1 -11) 
Khorana score, median (range) 
0 
1 
2 
3 
4 
5 
    1 (0 - 5) 
  93 (28.2 %) 
105 (31.8 %) 
  83 (25.2 %) 
  39 (11.8 %) 
    9 (2.7 %) 
    1 (0.3 %) 
Khorana ≥3   49 (14.8 %) 
IMPROVE score, median (range)     4.5 (1 - 14.5) 
IMPROVE ≥7   56 (16.9 %) 
Data are reported as number of patients (%), unless otherwise indicated 437 
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Table 2. Number of bleeding and thrombotic events during hospitalization and after discharge 455 
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 During hospitalization 
n = 330  
After discharge 
n = 289 * 
Bleeding 9 25 
 Major bleeding 4 11 
 Clinically relevant non-major bleeding 2 1 
 Minor bleeding 3 13 
Venous thromboembolism 12 2 
Deep vein thrombosis 
 Symptomatic 
 Incidental 
4 
1 
3 
1 
1 
0 
Pulmonary embolism 
 Symptomatic 
 Incidental 
8 
1 
7 
1 
1 
0 
Death 41 134 
Cardiovascular event 
 Acute coronary syndrome 
 Ictus 
 
0 
0 
 
0 
0 
Re-hospitalization - 56  
* 41 participants died during hospitalization 456 
 457 
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Table 3. Characteristics of patients with clinically relevant bleeding during hospitalization and after discharge 
Patient ID Cancer type Metastasis Bleeding site Units transfused Days since hospitalization 
Bleeding events during hospitalization      
  On-thromboprophylaxis      
    Major bleeding      
       45 Bladder Yes Upper gastrointestinal 6 4 
     292 Bladder No Vaginal 12 8 
    Clinically relevant non-major bleeding      
     181 Colorectal Yes Lower gastrointestinal - 2 
     244 Prostate No Hematuria - 5 
  Off-thromboprophylaxis      
   Major bleeding      
     192 Pancreas Yes Upper gastrointestinal 2 8 
     268 Prostate No Urinary tract 2 5 
Bleeding events after discharge     Days since discharge 
  On-thromboprophylaxis      
    Major bleeding      
     124 Colorectal No Lower gastrointestinal  3 63 
  Off-thromboprophylaxis      
   Major bleeding      
       94 Colorectal Yes Lower gastrointestinal  3 40 
     103 Breast No Intracranial   88 
     133 Prostate Yes Lower gastrointestinal  23 30 
     192 Pancreas Yes Lower gastrointestinal  2 15 
     217 Stomach Yes Upper gastrointestinal  4 28 
     220 Lung Yes Lower gastrointestinal  10 50 
     227 Stomach No Lower gastrointestinal  3 80 
     262 Biliary Yes Upper gastrointestinal  3 7 
     292 Bladder No Vaginal 3 11 
     294 Bladder Yes Fatal retroperitoneal bleeding  - 36 
Clinically relevant non-major bleeding      
       63 Lung Yes Lower gastrointestinal 0 50 
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Table 4. Patients with venous thromboembolic events during hospitalization 
Patient ID Cancer type Metastasis VTE Incidental Reason for hospitalization Days since 
admission 
On-thromboprophylaxis       
    78* Prostate No Proximal DVT No Heart failure 4 
   228† Lung Yes Segmental and subsegmental PE No Heart failure 12 
Off-thromboprophylaxis       
    18  Pancreas No Lobar PE Yes Jaundice 2 
    20 Colorectal Yes Segmental PE Yes Asthenia, weight loss, physical decay 9 
    27 Gynecological Yes Segmental PE Yes Worsening ascitis 15 
    65 Head-neck No Bilateral proximal DVT Yes Asthenia, weight loss, physical decay 2 
    71 Gynecological Yes Lobar PE Yes Ascitis 10 
  174 Colorectal Yes Segmental PE Yes Abdominal pain 5 
  185 Stomach No Segmental PE Yes Nausea, abdominal pain 11 
  201 Stomach Yes Segmental PE Yes Jaundice, abdominal pain  2 
  231 Stomach No External iliac DVT Yes Refractory pain, anemia 7 
  324 Lung Yes Distal DVT Yes Pleural effusion 6 
DVT = deep vein thrombosis; PE = pulmonary embolism; * the participant received 2 days of Enoxaparin 4000 IU prior to the event; † the participant received 6 
days of Enoxaparin 6000 IU prior to the event. 
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